Drug Trial Radar · NCT07462377
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Mar 31, 2026
Primary completion
Jul 2029
Study completion Jul 2029
Sponsor
- Lead sponsor
- EpiBiologicsIndustry
- Sponsor type
- Industry
- First posted
- Mar 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Conditions
- Epidermal Growth Factor
- Epidermal Growth Factor Receptor
- Epidermal Growth Factor Receptor Gene Mutation
- Non Small Cell
- Non Small Cell Lung
- Non Small Cell Lung Cancer
- Head and Neck
- Head and Neck Cancer
- Head and Neck Cancers
- Head and Neck Squamous Cell Cancer
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma HNSCC
- NSCLC (Non-small Cell Lung Cancer)
- HNSCC
- EGFR
Interventions
EPI-326Drug
EPI-326 is a tissue-selective bispecific antibody for EGFR-driven cancers. EPI-326 will be administered in the clinic via IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of the safety and tolerability of EPI-326Time frame: Up to 3 years.
- Determination of the recommended dose and schedule for EPI-326 administrationTime frame: Up to 3 years.
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Site 105 - START Los Angeles
Los Angeles, California · Recruiting
Site 104 - START New Jersey
East Brunswick, New Jersey · Recruiting
Site 107 - START New York - Long Island
Lake Success, New York · Recruiting
Sarah Cannon and HCA Research Institute
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Site 102 - START San Antonio
San Antonio, Texas · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
Kaohsiung City, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.